Abbott has secured a major regulatory win for its new dual-energy heart treatment technology, announcing European approval for its TactiFlex Duo Ablation Catheter on January 20, 2026. The company reported that the first commercial procedures were completed in the same week as the CE Mark approval.
Two Treatment Options in One Device
What makes this technology particularly noteworthy? The TactiFlex Duo catheter represents a significant advance in treating atrial fibrillation (AFib), offering physicians the ability to switch between two different energy types during a single procedure. The device delivers both radiofrequency energy, which uses heat to destroy problematic heart tissue, and pulsed field ablation (PFA) energy, which uses electrical pulses to target cells causing abnormal rhythms while reducing risk to surrounding tissues.
Prof. Isabel Deisenhofer, head of Electrophysiology at German Heart Center Munich and the first physician to use the device commercially, emphasized the catheter’s versatility: “TactiFlex Duo’s most unique feature is its dual options that allow physicians to seamlessly switch treatment during a procedure based on the patient’s personalized needs and anatomy.”
This approval comes at a critical time for European healthcare systems. Approximately eight million Europeans over age 65 currently live with AFib, a number that’s expected to double within the next three decades. For many patients who don’t respond to medication, cardiac ablation procedures offer the best chance for long-term symptom relief.
Clinical Evidence Supports Approval
The CE Mark approval wasn’t granted on technical innovation alone. Abbott’s FOCALFLEX study, conducted across clinical centers in the European Union, United Kingdom, and Australia, demonstrated both safety and effectiveness for AFib treatment.
Clinical data presented at APHRS 2025 showed remarkable success rates — 100% acute success in the deep sedation group and 99.6% in the general anesthesia group, with a median total pulmonary vein ablation time of just 45.5 minutes. These results build on Abbott’s previous success with its Volt PFA System, which achieved a 99.1% pulmonary vein isolation success rate in its own CE Mark study.
“AFib is a progressive disease that becomes harder to treat over time, and there is not a one-size-fits all approach,” explained Dr. John Silberbauer from Sussex Cardiac Centre in Brighton. “TactiFlex Duo allows me to safely tailor each ablation treatment to the patient’s anatomy, and results show that it consistently improves symptoms and quality of life for many.”
Integration with Existing Systems
The technology doesn’t stand alone. TactiFlex Duo integrates with Abbott’s EnSite X EP System, which creates detailed three-dimensional maps of the heart to help physicians pinpoint and treat arrhythmia sources. This builds on the previous generation’s flexible electrode tip and contact force sensing capabilities, now with added PFA energy delivery.
But who exactly stands to benefit from this dual-energy approach? According to Dr. Christopher Piorkowski, chief medical officer of Abbott’s electrophysiology business, the technology serves a broad range of complex patient populations.
“The TactiFlex Duo Catheter provides another advanced tool to Abbott’s growing PFA portfolio for treating patients with more complex cases such as those with co-existing heart disease and heart failure, long-lasting AFib, ventricular arrhythmias and patients with a history of failed ablations,” he stated.
U.S. Approval on the Horizon?
What about availability beyond Europe? Abbott completed enrollment for its FLEXPULSE IDE trial evaluating the device for AFib treatment in the United States in 2025. More significantly, the FDA granted the technology Breakthrough Device Designation in October 2025 specifically for treating ventricular tachycardia using PFA.
This marks Abbott’s third major electrophysiology approval in less than a year, following the Volt PFA System’s FDA and CE Mark approvals in 2025. The rapid succession of regulatory wins suggests a significant investment by the company in cardiac rhythm management technologies.
For the millions of Europeans living with the daily burden of atrial fibrillation, this dual-energy technology represents more than just another medical device — it offers the possibility of customized treatment that adapts to their specific cardiac anatomy and condition. That flexibility might just be the key to better outcomes for those who’ve struggled with this challenging and increasingly common heart rhythm disorder.
